Cellyan Biotechnology Co., Ltd (HKPD)

Cellyan Biotechnology Income Statement

Financials in millions USD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023
Revenue	20.31	16.69	12.56
Revenue Growth (YoY)	21.72%	32.91%	-
Cost of Revenue	17.9	13.13	9.82
Gross Profit	38.21	29.82	22.37
Selling, General & Admin	2.22	1.89	1.76
Other Operating Expenses	0.07	0.06	-0.06
Total Operating Expenses	2.28	1.95	1.7
Operating Income	35.93	27.87	20.68
Interest Income	0	0	0
Interest Expense	-0.1	-0.08	-0.02
Other Non-Operating Income (Expense)	-0.1	-0.08	-0.02
Total Non-Operating Income (Expense)	-0.19	-0.16	-0.05
Pretax Income	0.04	1.53	1.02
Provision for Income Taxes	0.06	0.2	0.02
Net Income	-0.03	1.33	1
Net Income to Common	-0.03	1.33	1
Net Income Growth	-	33.21%	-
Shares Outstanding (Basic)	9	7	7
Shares Outstanding (Diluted)	9	7	7
Shares Change (YoY)	22.08%	8.05%	-
EPS (Basic)	-0.00	0.18	0.15
EPS (Diluted)	-0.00	0.18	0.15
EPS Growth	-	23.29%	-
Free Cash Flow	0.5	-0.45	1.61
Free Cash Flow Per Share	0.05	-0.05	0.24
Gross Margin	188.11%	178.68%	178.19%
Operating Margin	176.87%	166.99%	164.69%
Profit Margin	-0.13%	7.97%	7.95%
FCF Margin	2.46%	-2.68%	12.84%
EBITDA	37	28.79	21.39
EBITDA Margin	182.16%	172.53%	170.38%
EBIT	35.93	27.87	20.68
EBIT Margin	176.87%	166.99%	164.69%
Effective Tax Rate	174.92%	12.86%	2.21%

Updated Mar 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q